BioSpace News Archive

Aerami Therapeutics (“Aerami”) today announced senior leaders are scheduled to participate in the Biotech Showcase™ 2023, with a presentation scheduled for 2 PM (PST) on Monday, January 9, 2023, during the 41st Annual J.P. Morgan Healthcare Conference Week in San Francisco, California.

Qualigen Therapeutics, Inc. while also commercializing diagnostics, today shares an update on its majority-owned subsidiary, NanoSynex Ltd. (“NanoSynex”), the progress made during 2022, and objectives for 2023 concerning the commercialization plans for its innovative rapid Antimicrobial Susceptibility Test (AST).

Insilico Medicine (“Insilico”), a clinical stage, end-to-end artificial intelligence (AI)-driven drug discovery company, held the launch ceremony for Life Star – a 6th generation Intelligent Robotics Drug Discovery Laboratory – in Suzhou BioBAY Industrial Park on Dec. 29.

Acasti Pharma Inc. today announced that it will host a conference call on Tuesday, January 10, 2023 at 4:30 p.m. ET to review the recently reported preliminary topline results from two separate Phase 1 pharmacokinetic (PK) studies for GTX-101 and GTX-102.

Blacksmith Medicines, Inc. announced additions to its science advisory team to help advance its emerging precision oncology programs focused on novel synthetic lethality targets involved in the DNA Damage Response.

With its exclusive global license to the TABMELT technology for pharmaceutical use, Vivera is pleased to announce the expansion of the Company’s international presence with the recent grant of the TABMELT patent in Israel.

CNS Pharmaceuticals, Inc. announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the Virtual Investor 2023 Companies to Watch Event on Wednesday, January 18, 2023 at 10:00 AM ET.

Morphic Therapeutic today announced that Praveen Tipirneni, M.D., President and Chief Executive Officer, will present at the 41 st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 2:15 PM PST.

Generate Biomedicines today announced that it will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco later this month.

Tempus, a leader in artificial intelligence and precision medicine, today announced a prospective study (NCT05257551), in collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), that aims to identify biomarkers of response in patients with small cell lung cancer (SCLC).